Exelixis

Exelixis, Inc. is an American biotechnology company that focuses on the discovery, development, and commercialization of therapies for oncology. The company emphasizes small-molecule inhibitors that target kinases involved in tumor growth and angiogenesis, with cabozantinib serving as its lead program. Cabozantinib is marketed under the brand name Cabometyx and has been developed for multiple cancer indications. The program began in-house and has received regulatory approvals for several cancers, notably advanced renal cell carcinoma, with earlier development of cabozantinib as Cometriq for metastatic medullary thyroid carcinoma.

Exelixis operates with a global development and commercialization strategy that includes a long-standing collaboration with Ipsen. Ipsen holds rights to cabozantinib outside the United States, while Exelixis retains U.S. rights and leads the development and commercialization efforts in the United States. This arrangement positions Cabometyx as a key product in Exelixis’s portfolio and supports broader international access through partnership.

Headquartered in Alameda, California, Exelixis is publicly traded on the Nasdaq Global Select Market under the ticker EXEL. The company maintains a pipeline of oncology programs beyond cabozantinib, including early-stage and exploratory endeavors, and pursues strategic collaborations to expand indications and combinations for cabozantinib-based therapies.

Overall, Exelixis presents itself as a growth-focused biopharmaceutical company centered on advancing targeted cancer therapies and expanding the clinical and commercial reach of its cabozantinib portfolio.